Cost variation analysis of oral anti-diabetic agents available in Indian market
Keywords:Price variation, Oral anti diabetic drugs, Cost variation, Cost ratio, Diabetes mellitus
Background: The objective of this study was to analyze cost variations of oral antidiabetic drugs available in Indian market.
Methods: An observational study was carried out using CIMS (current index of medical specialities), (July 2020 to October 2020) and 1 mg.com, where difference in the maximum and minimum price of a particular drug, manufactured by different pharmaceutical companies, in the same strength, number and dosage form was compared and the percentage variation in price was calculated. Data was analyzed using descriptive statistical analysis.
Results: The minimum and maximum percentage price variation for different classes of drugs respectively is as follows- in single drug therapy, the price variation between a sulfonylurea group of drugs glibenclamide (5 mg) shows maximum price variation of 400%, while glipizide (2.5 mg) shows variation of 81.8%. In biguanides, thizolidinediones and DPP4 inhibitor groups of drugs, metformin (500 mg), pioglitazone (30 mg) and vildagliptin show maximum price variation of 334.78%, 307 % and 264.6% respectively. In α- glucosidases inhibitor group of drugs voglibose (0.2 mg) shows maximum price variation of 284%. In meglitinides group of drugs, nateglinide (60 mg) shows maximum price variation of 284.6 %. In combination drug therapy, glimepiride and metformin combination (2+500 mg SR) shows the maximum variation up to 352.8%.
Conclusions: The percentage cost variation of different brands of the same drug manufactured in India is very wide and the reason behind marketing a drug should be directed towards maximizing the benefit of therapy and minimizing negative personal and economic consequences.
Mayor S. Diabetes affecting nearly 250 million adults in the world. Br Med J. 2006;333:1191.
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7(1):45-8.
International Diabetes federation. Diabetes atlas. 6th ed. IDF; 2003.
Kyle JS. A general overview of oral hypoglycemics for type 2 diabetes. Wyoming drug utilization review. 2008.
Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathological approach. 6th ed. New York, NY: McGraw-Hill; 2005: 1333.
Powers AC. Diabetes mellitus. In: Braunwald E, Fauci AS, Kasper DL, Mauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicines. 15th ed. New York, NY: McGraw- Hill; 2001: 2109-37.
Sakthivel S. Access to essential drugs and medicines. In: Commission on Macroeconomics and Health, Financing and delivery of health care services in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005: 185-210.
Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India.Int J Basic Clin Pharmacol 2016;5:1636-40.
Shukla AK, Sharma P. Cost variation study of antidepressant drugs. Int J Basic Clin Pharmacol. 2016;5:1816-21.
Standards of Medical Care in Diabetes. American Diabetes Association Diabetes Care. 2014;37(1):14-80.
Lalan HN, Borde MK, Ray IM, Deshmukh YA. Cost Variation Study of Antidiabetics: Indian Scenario. Indian J Appl Res. 2014;4(5):420-1.
Rao KS, Nundy M, Dua AS, National commission on macroeconomics and health, financing and delivery of health care services in India. Government of Indi:, Delivery of Health Services in the Private Sector. New Delhi: Ministry of Health and Family Welfare. 2005: 89-104.
Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries BMJ Open. 2017;7:14287.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160:3.